Company Filing History:
1 out of 76 
1 out of 1 
1 out of 81 
Years Active: 2025
Title: The Innovations of Jayoung Kang
Introduction
Jayoung Kang is a notable inventor based in Buan-gun, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on enhancing the specificity and affinity of antibodies for better diagnostic applications.
Latest Patents
Jayoung Kang holds a patent for a monoclonal antibody specifically binding to CCSP-2 and its use. The invention relates to a monoclonal antibody that targets the EGF2 domain of colon cancer secreted protein-2 (CCSP-2). This antibody demonstrates significantly increased affinity compared to existing peptides and improved specificity compared to other antibodies targeting CCSP-2. The potential for accurate diagnosis through specific detection of CCSP-2 at the protein level is a promising aspect of this invention.
Career Highlights
Throughout his career, Jayoung Kang has worked with various organizations, including the Asan Foundation and Edisbiotech Co., Ltd. His experience in these institutions has contributed to his expertise in the field of monoclonal antibodies and cancer research.
Collaborations
Jayoung Kang has collaborated with several professionals in his field, including Seung-Jae Myung and Eun-Ju Do. These collaborations have likely enhanced his research and development efforts in biotechnology.
Conclusion
Jayoung Kang's innovative work in monoclonal antibodies represents a significant advancement in cancer diagnostics. His contributions are expected to lead to more accurate detection methods, ultimately benefiting patient care and treatment outcomes.